Non-Hodgkin Lymphoma Imaging Spectrum in Children, Adolescents, and                     Young Adults

Marie, Eman; Navallas, María; Katz, Douglas S.; Farajirad, Elnaz; Punnett, Angela; Davda, Sunit; Shammas, Amer; Oudjhane, Kamaldine; Vali, Reza

doi:10.1148/rg.210162

Cited by 5 publications

(4 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[20][21][22] Current data support increased use in bone sarcoma and non-Hodgkin lymphoma, but larger prospective multicenter studies are needed to clearly define their usefulness. 23 Only a limited number of children with mGCT evaluated by 18 F-FDG PET/CT are reported in the literature, [24][25][26] however. The largest series by Hart et al 27 describes 9 children with mGCT who underwent 18 F-FDG PET/CT during a period of 8 years in a single center.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Children With Germ Cell Tumor After Chemotherapy

De Pasquale,

D’Angelo,

Crocoli

et al. 2024

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Background/Aim: 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a diagnostic tool widely used in adult oncology and some pediatric oncological settings. There are no established recommendations for the use of this imaging modality in pediatric malignant germ cell tumors (mGCT), however. Our aim is to evaluate the role of 18F-FDG PET/CT in the restaging of mGCT after chemotherapy in children and adolescents. Methods: We retrospectively reviewed patients with mGCT treated in Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) centers who underwent 18F-FDG PET/CT between 2011 and 2021. Results: Seventeen patients (median age 13 y) were included in the study. In 14 patients, 18F-FDG PET/CT was performed at diagnosis; 12 showed pathologic uptake. The 2 18F-FDG PET/CT negative cases were histologically defined as yolk sac tumor (YST) and mixed (chorioncarcinoma, YST). Nine of the 12 patients who had pathologic 18F-FDG PET/CT at diagnosis repeated the examination after neoadjuvant chemotherapy, before, second look surgery. In 5 cases, no pathologic uptake was evident. Histology showed necrosis alone in 4 cases and necrosis and mature teratoma in 1. In 3 of the 6 cases with pathologic uptake (2 of 6 patients did not perform the examination at diagnosis), histology showed persistence of malignant component, whereas in the remaining 3 cases, necrosis and mature teratoma were present. Conclusion: In our review of a series of children with mGCT, 18F-FDG PET/CT after neoadjuvant chemotherapy showed 1 of 5 false negatives and was unable to discriminate between residual malignant component and mature teratoma.

show abstract

Section: Discussionmentioning

confidence: 99%

“…18 F-FDG PET/CT has an established role in the staging of some pediatric cancers, such as Hodgkin Lymphoma, rhabdomyosarcoma, and non-MIBG avid neuroblastoma 20–22 . Current data support increased use in bone sarcoma and non-Hodgkin lymphoma, but larger prospective multicenter studies are needed to clearly define their usefulness 23 …”

Section: Discussionmentioning

confidence: 99%

Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Children With Germ Cell Tumor After Chemotherapy

De Pasquale,

D’Angelo,

Crocoli

et al. 2024

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

“…The incidence of NHL increases with age, reaching upwards of 150 cases per million individuals in the adult population [ 9 ]. Out of many types of NHL, B-cell lymphoma is the most common type reported among pregnant patients [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…Out of many types of NHL, B-cell lymphoma is the most common type reported among pregnant patients [ 6 ]. Risk factors for the development of NHL are a history of human immunodeficiency virus, solid organ transplantation, and X-linked lymphoproliferative syndrome, as well as those with prior successful treatment of HL [ 9 ]. Sex hormones may have an influence on the development of NHL-follicular lymphoma, but have not been found to have an association with other NHL-subtypes [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Imaging evaluation of lymphoma in pregnancy with review of clinical assessment and treatment options

et al. 2023

Self Cite

View full text Add to dashboard Cite

Lymphoma-related malignancies can be categorized as Hodgkin’s lymphoma (HL) or non-Hodgkin’s lymphoma (NHL) based on histologic characteristics. Although quite rare during pregnancy, HL and NHL are the fourth and fifth most common malignancies during the pregnancy period, respectively. Given the rarity of lymphoma among pregnant patients, radiologists are usually unfamiliar with the modifications required for staging and treatment of this population, even those who work at centers with busy obstetrical services. Therefore, this manuscript serves to not only review the abdominopelvic imaging features of lymphoma in pregnancy, but it also discusses topics including birthing parent and fetal lymphoma-related prognosis, both antenatal and postpartum, current concepts in the management of pregnancy-related lymphoma, as well as the current considerations regarding birthing parent onco-fertility. Graphical abstract

show abstract

Nuclear medicine techniques in paediatric body oncology: Present and future

Meshaka,

Biassoni,

Chambers

et al. 2023

EJC Paediatric Oncology

View full text Add to dashboard Cite

Non-Hodgkin Lymphoma Imaging Spectrum in Children, Adolescents, and Young Adults

Cited by 5 publications

References 77 publications

Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Children With Germ Cell Tumor After Chemotherapy

Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Children With Germ Cell Tumor After Chemotherapy

Imaging evaluation of lymphoma in pregnancy with review of clinical assessment and treatment options

Nuclear medicine techniques in paediatric body oncology: Present and future

Contact Info

Product

Resources

About